

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and AssureRx Health, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Brian Athey, PhD is both an employee of the University of Michigan ("University") and a partial owner of AssureRx Health, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents ("Regents") of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Brian Athey, a Professor and Chair in the Department of Computational Medicine & Bioinformatics and Professor of Psychiatry and Internal Medicine, is the partial owner of a for-profit company called AssureRx Health, Inc. (the "Company"). The Company was formed recently to commercialize industry-leading personalized medicine technology. The Company wishes to fund a project entitled "Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients with Major Depressive Disorder" (HUM00083781, 14-PAF03125) under the direction of Masoud Kamali, MD, in the University's Department of Psychiatry, which requires the use of facilities and resources of the University.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is expected to be three (3) years and the amount of funding support is anticipated at \$152,140. Since research projects are often amended, this agreement includes provisions for changes in time, amount, and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.


Impact of the Agreement:

The Agreement will support an effort by Dr. Kamali to use his expertise and University resources to evaluate the response and long-term impact of the use of GeneSight Psychotropic in patients with Major Depressive Disorder.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with AssureRx Health, Inc.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "S. Hu", written in a cursive style.

S. Jack Hu
Interim Vice President for Research

July 2014